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Abstract
The identity and subcellular sources of endocannabinoids (eCBs) will shape their ability to affect synaptic transmission and,
ultimately, behavior. Recent discoveries support the conclusion that 2-arachidonoyl glycerol, 2-AG, is the major signaling
eCB, however, some important issues remain open. 2-AG can be synthesized by a mechanism that is strictly Ca
2+-
dependent, and another that is initiated by G-protein coupled receptors (GPCRs) and facilitated by Ca
2+. An important
question is whether or not the 2-AG in these cases is synthesized by the same pool of diacylglycerol lipase alpha (DAGLa).
Using whole-cell voltage-clamp techniques in CA1 pyramidal cells in acute in vitro rat hippocampal slices, we investigated
two mechanistically distinct eCB-mediated responses to address this issue. We now report that pharmacological inhibitors
of DGLa have quantitatively different effects on eCB-mediated responses triggered by different stimuli, suggesting that
functional, and perhaps physical, distinctions among pools of DAGLa exist.
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Introduction
The cannabinoid system affects behavior and regulates many
synaptic functions. There are two major endogenous ligands for
CB1R (the main cannabinoid receptor in the brain): the eCBs N-
arachidonoyl-ethanolamine (anandamide [1]) and 2-arachidonoyl-
glycerol (2-AG) [2,3,4]. Anandamide and 2-AG have different
synthetic and degradative pathways, and the eCB-dependent
regulation of neuronal communication will be determined by the
identity and subcellular sources of the eCB involved. Evidence is
converging on the conclusion that 2-AG is the primary phasic
signaling eCB at numerous synapses in the brain [5], whereas
anandamide may regulate tonic eCB actions [6]. Strong support
for the former inference comes from recent molecular genetic
studies in which the primary synthetic enzyme for 2-AG, DAGLa,
was knocked out in lines of mutant mice [7,8], causing a reduction
of ,80% in basal 2-AG levels. Purely Ca
2+-dependent eCB
signaling – depolarization-induced suppression of inhibition, DSI
[9,10], and excitation, DSE [11] – and eCB signaling mediated by
GPCRs, including group I metabotropic glutamate receptors
(mGluRs), i.e., (eCBmGluR) [12,13] were essentially abolished by
DAGLa deletion. Yet, additional issues remain unresolved. For
example, it is not known if the same DAGLa source (pool)
provides 2-AG for both DSI and eCBmGluR.
eCBs mediate different forms of synaptic plasticity [14], hence
knowledge of the cellular source(s) of eCBs is an important issue,
yet one that cannot be addressed with a global knock-out strategy.
Accordingly, we have taken a pharmacological approach, using
two DAGL inhibitors to determine whether the pools of Ca
2+ -
and mGluR-dependent of 2-AG are distinguishable. If eCB
responses to both stimuli were equally sensitive to the inhibitors, it
would argue that the sources of 2-AG are the same, whereas
marked differences in sensitivity would indicate that on a
functional, and perhaps physical, level they differ. We report that
the DAGL that mediates hippocampal DSI and eCBmGluR, can be
functionally separated into two pools. Understanding the differ-
ences in subcellular regulation of 2-AG may lead to new modes for
controlling eCB actions.
Results
While recent molecular biological evidence supports the
conclusion that 2-AG is the signaling eCB, pharmacological tools
can be useful in teasing apart subtle features of the DAGLa/2-AG
system that are not revealed by constitutive knock-out strategies.
To test the hypothesis that both DSI and eCBmGluR are mediated
by the same source of 2-AG, we began by bath-applying DAGL
inhibitors to voltage-clamped hippocampal CA1 cells in acute
slices in which inhibitory post-synaptic currents (IPSCs) were
pharmacologically isolated (see Methods). External application of
the selective and potent inhibitor, OMDM-188 [15], 5 mM, or the
less-selective inhibitor, tetrahydrolipstatin (THL), 10 mM, abol-
ished DSI of evoked IPSCs (eIPSCs). As a percentage of baseline
(100%) level, eIPSCs in the various conditions were: Vehicle:
60.264.0%, n=20; OMDM-188: 95.761.5%, n=34; THL:
92.861.4%, n=35 (Fig. 1). We also tested two inhibitors of the
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inhibitors do not affect anandamide. Both JZL 184 [16], 1 mM,
and OMDM-169 [15], 2 mM, significantly prolonged tdecay of DSI
(cf [17]), thus providing an independent cross-check on the
hypothesis that DSI is mediated by 2-AG (Fig. 2).
Unlike DSI, eCBmGluR-dependent eIPSC suppression (e.g.,
Fig. 3a) was highly resistant to external application of DAGL
inhibitors. Responses to initial applications of DHPG were not
different (p.0.05) whether the slices were treated with vehicle, or
DAGL inhibitors. Even when evoked by repeated 4-min bath-
applications of a high concentration of the group I mGluR agonist,
DHPG., 50 mM, eCBmGluR was only slightly, though statistically
significantly, reduced by OMDM-188 (1
st DHPG: eIPSC
reduction to 54.464.3% of baseline; 2
nd DHPG: to 65.665.2%
of baseline; n=15, p,0.005, Figs. 3b, 3c) or THL (1
st DHPG: to
58.963.1% of baseline; 2
nd DHPG: to 64.763.3% of baseline;
n=13, p,0.05; Figs. 3d, 3e). In vehicle-treated cells there were no
significant reductions in the responses to repeated DHPG
applications: 1
st DHPG: to 47.564.5% of baseline; 2
nd DHPG:
to 47.364.4% of baseline; n=8, p.0.5, Figs. 3f, 3g). Though
resistant to DAGL inhibitors, eCBmGluR was strongly reduced by
the CB1R antagonist, SR141716A (10 mM) (1
st DHPG: to
70.668.1% of baseline; 2
nd DHPG in SR141716A: to
89.965.2% of baseline; n=5, p,0.05; data not shown),
confirming previous reports [12,13], that eCBmGluR is CB1R-
dependent.
Because intracellular application could conceivably be more
effective on eCBmGluR [18], we tested the DAGL inhibitors by
applying them intracellularly via infusion through the whole-cell
pipette. We observed dose-dependent reduction in DSI with internal
OMDM-188 (2–20 mM)(Figs. 4a, 4b; n=94), and similar significant
reductions caused by internal application of THL (10 mM, n=19)
(Fig. 4b). Internal DAGL inhibition did not alter eCBmGluR in the
same way (Figs. 4c, 4d). We examined the effects of OMDM-188 in
detail and found that, even in the same cells in which DSI was
reduced to negligible levels (#5% eIPSC reduction, n=28/35 cells;
see Fig. 4d, dotted oval), eCBmGluR still suppressed eIPCSs by
,50%, i.e., OMDM-188 had almost no effect on eCBmGluR.
Internal infusion of 5 mM OMDM-188 (filled triangles in Fig. 4d),
reduced either eCBmGluR or DSI only slightly. Interestingly, data
from the cells in which 10 or 20 mM OMDM-188 was least effective
fell along a regression line around which the 5 mM data also
scattered. This could mean that in these cases diffusion of 10 or
20 mM OMDM-188 out of the pipettes was incomplete, resulting in
a lower-than-expected internal concentration of the drug.
To ensure that the DAGL antagonist had an opportunity to
equilibrate throughout the cells, we extended the observations and
reapplied DHPG at 15–20 min intervals with OMDM-188 (10 or
20 mM) in the internal solution. Indeed, with repetitive DHPG
application, eCBmGluR suppression of eIPSCs diminished (1
st
DHPG: to 51.562.5% of baseline; 2
nd DHPG: to 80.464.4% of
baseline; 3
rd DHPG: to 83.565.6% of baseline; n=8, p,0.001,
Figure 1. External application of DAGL inhibitors blocks DSI. (a) Representative DSI trial. Downward deflections are eIPSCs evoked at 4-s
intervals; DSI was evoked by a 3-s voltage step to 0 mV from the holding potential of -70 mV; depression of eIPSCs after a step is the period of DSI
(see text). Scale: 24 s/200 pA. (b) Bath application of OMDM-188 (5 mM) or THL (10 mM) essentially abolished DSI; K-S tests, p,0.01. Note: values ,0
represent eIPSCs that were greater than baseline amplitudes, not enhanced DSI. (c) Group data.
* p,0.001, one way ANOVA on ranks. Vehicle, n=20;
OMDM-188, n=34; THL, n=35.
doi:10.1371/journal.pone.0016305.g001
Functionally Distinct Pools of DAGL-Alpha
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16305Figs. 5a, 5b). The decrease in eCBmGluR did not reflect
spontaneous response ‘rundown’, because responses were stable
with infusion of vehicle (DMSO or ethanol) (1
st DHPG: to
44.064.7% of baseline; 2
nd DHPG: to 44.464.0% of baseline; 3
rd
DHPG: to 48.165.4% of baseline; n=7, p.0.5; Figs. 5e, 5f).
It was not clear whether the passage of time alone accounted for
the increased inhibitor efficacy, or whether suppression of
eCBmGluR by DAGL inhibition was use-dependent, i.e., whether
it was enhanced by repetitive stimulation. To distinguish the effects
of longer OMDM-188 infusions from those of repeated DHPG
application, in another group of cells we delayed the 1
st DHPG
application until 30–40 min after break-in, i.e., it was given at the
same relative time after break-in as the 2
nd DHPG application in
the original group (cf, Figs. 5b, 5d). The eCBmGluR eIPSC
suppression was the same in the two 1
st DHPG groups: (30–
40 min post-break-in: to 50.564.3% of baseline, n=11; 10–
20 min post-break-in: to 49.562.5% of baseline, n=16; n.s.
p.0.1). A 2
nd DHPG application (i.e., 50–60 min post-break-in)
given to cells receiving a delayed 1
st DHPG application, induced
less eIPSC depression (2
nd DHPG: to 73.464.3% of baseline; 1
st
DHPG: to 46.861.7% of baseline; n=5, p,0.01; Figs. 5c, 5d). As
a final check, we compared the magnitudes of the 2
nd DHPG
responses, obtained either 30–40 or 50–60 min post-break-in, and
found that they were indistinguishable (p.0.1, Figs. 5b, 5d).
Hence, gradual diminution in the eCBmGluR response depended
on the presence of both the DAGL inhibitor and repeated DHPG
stimulation, and could not be explained simply by the duration of
the inhibitor application.
The decline in eCBmGluR just described might reflect use-
dependent depletion of a pool of 2-AG. Two predictions would
Figure 2. Antagonists of the primary catabolic enzyme for 2-AG, monoacylglycerol lipase (MAGL), prolong DSI. Diamonds indicate
delivery of DSI-inducing voltage steps. Scale: 30 s/150 pA. (a) Bath application of MAGL inhibitors, JZL184 (1 mM) or OMDM-169 (2 mM), prolong DSI.
(b) Group data showing recovery DSI in the presence of DMSO (Veh), JZL184, or OMDM-169. The DSI-inducing voltage step ended 1 s prior to time 0.
The solid lines are best fitting single-exponential functions; the time constants of these functions were taken as the decay time constants (tdecay)o f
DSI. (c) Group data showing increases in tdecay of DSI in the indicated conditions. When applied for 40–120 min, JZL184 or OMDM-169, prolonged
DSI; tdecay was increased by ,40% (DMSO: 13.961.1 s, n=21; JZL184: 19.261.7 s, n=15; OMDM-169: 20.461.6 s, n=15; p,0.01, one way ANOVA).
doi:10.1371/journal.pone.0016305.g002
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deflections) and DSI trials (diamonds) in external OMDM-188, 5 mM. Note DSI is abolished despite continued suppression of eIPSCs by DHPG. (b)
Sample eIPSCs (each trace is the mean of 3) from the same cell in external OMDM-188. BL denotes the baseline response, and W, the response
obtained after washing out DHPG. DHPG was applied twice at 20-min intervals starting ,15–20 min after break-in. (d) As in (b), with THL in the saline.
(f) As in (b), with vehicle only in the saline. (c)(e)(g) Group data for experiments in (b), (d), and (f), respectively (paired-t-tests). OMDM-188-Out, n=15,
p,0.01; THL-Out, n=13, p,0.05; Vehicle-Out, n=8, p.0.5. Scale: 20 ms/200 pA.
doi:10.1371/journal.pone.0016305.g003
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concentration of DHPG should cause less of, or a slower onset of,
a reduction in the DHPG effect in the presence of a DAGL
inhibitor, and 2) inhibiting 2-AG synthesis by blocking another
major synthetic enzyme in this pathway, phospholipase Cb [19],
should also give rise to a use-dependent decline in eCBmGluR.
In experiments thus far, we used 50 mM DHPG, which is a high
concentration. To test the prediction that, in the presence of a
DAGL inhibitor, weaker stimulation of mGluRs would induce less
decline in eCBmGluR, we used 10 mM DHPG, with 20 mM
OMDM-188 in the internal solution. In this case, we did not
observe significant reduction in eCBmGluR, even with four
applications of DHPG given to the same cell (1
st DHPG: to
69.968.3% of baseline; 2
nd DHPG: to 72.967.5% of baseline; 3
rd
DHPG: to 70.169.9% of baseline; 4
th DHPG: to 74.669.2% of
baseline; n=5, p.0.1, data not shown). Hence, the declines in
eCBmGluR seen with the higher DHPG concentration were not
caused simply by repetitive activation of mGluRs.
In testing the second prediction, we found that both DSI and
eCBmGluR were induced in the presence of the PLC inhibitor,
U73122 (6 mM), however, when elicited repeatedly, eCBmGluR
suppression of eIPSCs diminished (1
st DHPG: eIPSCswerereduced
to 40.163.8% of baseline; 2
nd DHPG: to 67.366.9% of baseline;
3
rd DHPG: to 62.165.8% of baseline; n=5, p,0.01, Figs. 6a, 6b).
As expected, since DSI is normal (though eCBmGluR is abolished) in
the PLCb1
2/2 mouse [19], DSI was not altered by the PLC
inhibitor (eIPSC reduction to 66.863.5% of baseline, n=8).
If DSI and eCBmGluR arise from the same source of 2-AG, then
strong activation of one mechanism could alter the response of the
other. Because strong stimulation of mGluRs with bath-applied
DHPG has persistent effects on eIPSCs and DSI [14,20] that could
confound interpretation, we tested this prediction by determining if
repetitive elicitation of DSI would affect eCBmGluR. Pipettes
contained normal intracellular solution. We used two 4-min
applications of 50 mM DHPG separated by a 4-min period during
which DSI was elicited with 1-s depolarizing steps given at 12-s
intervals. The 12-s interval is too short to permit full recovery from
each DSI episode, with the result that eIPSCs are continually
suppressed by the DSI mechanism for the period of stimulation (cf,
[20]). As we have reported, an even longer period of repetitive
Figure 4. Intracellular application of DAGL inhibitors reduces DSI to a greater extent than it reduces eCBmGluR. (a) Intracellular infusion
of OMDM-188 reduced DSI; each symbol represents averaged DSI values (3 trials) from one cell. Only data for 5 mM (n=16) and 10 mM (n=38) groups
shown for clarity; both differ from Veh-In group, K-S test, p,0.01. (b) Group data. Includes results in (a), plus 2 mM (n=6), 20 mM (n=40) groups.
*
p,0.001, one-way ANOVA on ranks. (c) Sample continuous trace showing DSI trials and eIPSC suppression by eCBmGluR. Scale: 2 min/200 pA. (d)
Group data for experiments as in (c) with internal 5, 10 or 20 mM OMDM-188, or Veh only. DSI and eCBmGluR were measured, and eCBmGluR was plotted
against DSI for each cell. For the cells (n=28/35) within dotted oval, mean eIPSC reduction from baseline by DSI is 4.361.06%, mean eCBmGluR eIPSC
reduction is 49.062.32%. The straight line is a linear regression fit to the data for 10 and 20 mM DHPG (see text for discussion).
doi:10.1371/journal.pone.0016305.g004
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was possible that repetitive DSI stimulation could reduce the
magnitude of the subsequent eCBmGluR interval if a common 2-AG
pool was being tapped. Nevertheless, we found no evidence that this
occurred.TheeIPSCswere suppressedto49.865.8%ofbaselineby
50 mM DHPG before the repetitive DSI stimulation and to
48.464.8% of baseline afterwards; n=6, p.0.1; Figs. 6c, 6d). We
also tested the possibility that repetitive DSI stimulation might
somehow alter eCBmGluR if DSI expression was first blocked by
OMDM-188. Again, after a 4-min period of repetitive DSI, 50 mM
DHPG induced an eIPSC suppression to 48.665.2% of baseline,
not significantly different from the 1
st DHPG responses obtained
either 10–20 or 30–40 min post break-in, p.0.5 (data not shown).
Discussion
During a previous investigation [20], we noticed differences in
the efficacy of THL on DSI or eCBmGluR, however, in view of the
non-specific effects of THL, no definite conclusions could be
drawn. Moreover, it was unclear if both DSI and eCBmGluR were
mediated by the same eCB. In showing that DAGLa, and by
implication 2-AG, are involved in both processes, the recent
studies on DAGLa
2/2 mice [7,8] prompted an examination of
whether or not the same sources of 2-AG mediate eCB responses
evoked by different stimuli. The hypothesis that a unitary pool of
DAGLa supplies 2-AG for DSI and eCBmGluR predicts they
should be similarly affected by pharmacological inhibitors of
DAGLa. Using different inhibitors and modes of drug application,
we observed marked quantitative distinctions between the
responses produced by DSI and eCBmGluR. In particular: 1)
eCBmGluR is much less sensitive to block by DAGL-inhibitors than
is DSI, and 2) repetitive activation of the eCBmGluR system
enhanced the effect of DAGL inhibition, whereas such use-
dependence was not a feature of the block of DSI.
The differences in sensitivity to the DAGL inhibitors were
obvious even when both responses were recorded in the same cell,
ruling out systematic differences between experiments. Differences
in inhibitor- enzyme interactions are also ruled out, as DAGLa
Figure 5. Use-dependent reduction of eCBmGluR with internal DAGL inhibitor. (a) Sample eIPSCs (each trace is the mean of 3) from the same
OMDM-188-loaded (20 mM in the pipette) cell in the indicated conditions. BL denotes the baseline response, and W, the response obtained after
washing out DHPG. DHPG was applied 3 times at 20-min intervals starting ,15–20 min after break-in. (c) As in (a) except that the 1
st DHPG
application was given ,40 min after break-in – i.e., at the same time as the 2
nd DHPG application in (a) – and the 2
nd one at 50–60 min after break-in.
(e) As in (a), with vehicle only present in the internal solution. (b)(d)(f) Group data for experiments in (a), (c), and (e), respectively.
*p,0.001, one way
repeated ANOVA; Scale: 20 ms/200 pA.
doi:10.1371/journal.pone.0016305.g005
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different pools of DAGLa provide 2-AG in the two cases. The
hypothetical pools would not simply represent differences in spatial
localization along the pyramidal cell: with external application the
inhibitors have equal access to the surface of the cells, but had only
slight effects on eCBmGluR, despite abolishing DSI. A plausible
explanation for the differing efficacy of internal and external
application on eCBmGluR is that the DAGLa responsible for
eCBmGluR is much less accessible to externally applied inhibitor.
The suggestion of different pools of DAGLa is in good
agreement with previous observations. For example, the DAGLa
involved in eCBmGluR is found in dendrites apposed to glutamate
releasing nerve terminals [21,22,23]. In contrast, DAGLa has not
been reported near perisomatic GABAergic synapses like those we
have studied [21,22]. Since eCBs can spread longitudinally along
cell structures for only ,#10 mm [24], 2-AG produced by
DAGLa near excitatory synapses, which are located on CA1
pyramidal cell dendrites .50 mm from the somata, is most
unlikely to account for DSI. While the failure to have detected
DAGLa in pyramidal cell somata may reflect technical limitations
in available morphological tools, it does highlight the possibility
that different parts of a cell employ different pools of DAGLa for
generating eCBs. We also note, however, that while this seems to
be a parsimonious proposal, the lack of identification of the
DAGLa responsible for DSI means that other possibilities are not
ruled out. For example, our data would be compatible with
differences in DAG (rather than DAGLa) pools. DAG can be
produced by several mechanisms besides PLC [5]. We confirm the
2-AG produced by mGluRs is dependent on PLCb, but knocking
out [19], or inhibiting [20] PLCb does not affect hippocampal
DSI. Since DSI is dependent on DAGLa, and therefore probably
on 2-AG, it could be mediated by a source of DAG that is distinct
from that underlying eCBmGluR. Interestingly, use-dependence of
eCBmGluR reduction was seen when PLC, rather than DAGL, was
inhibited, supporting the concept that the DAGLa-PLC pathway
is upstream of the depletable source of 2-AG for eCBmGluR.
Attempts to use DAGLa inhibitors to probe the eCB system
have produced controversial results [18,20,25,26]. We had
observed that external, though not internal, THL application
affected DSI [26], and Min et al. [25] arrived at conclusions that
are diametrically opposed to our present observations. Probably
the use of higher concentrations of the inhibitors, longer
application times, and repetitive activation of the 2-AG-dependent
responses are the primary explanations for the reported variability.
In particular, difficulties in bath- or internally-applying these
lipophilic agents to cells in brain slices could account for the
requirement for higher concentrations, especially with intracellular
techniques, because restricted efflux from whole-pipettes can result
from partial electrode occlusion or adherence of the drugs to
pipette glass. Nevertheless, the possibility of non-specific effects
must also be kept in mind.
The use-dependence of the reduction in eCBmGluR is puzzling,
and while direct evidence is not available, one speculative scenario
is intriguing: decoupling of 2-AG synthesis and release could partly
account for the data. For example, if the pool of DAGLa-
dependent 2-AG that is present in unstimulated cells [4,7,8] could
be mobilized by mGluR activation, its release would not be closely
tied to DAGLa stimulation. Release from such a pool could persist
after DAGLa was inhibited, decreasing in a use-dependent way as
the preformed 2-AG pool diminished. If such decoupling were
greater for eCBmGluR than DSI, it could also account for their
different sensitivities to DAGL inhibitors. Finally, 2-AG release
from an existing pool could explain why knocking out PLCb
abolishes eCBmGluR [19], while a potent PLC inhibitor was
Figure 6. Regulation of eCBmGluR. (a) Sample eIPSCs (each trace is the mean of 3) from the same U73122-loaded cell in the indicated conditions
(U73122, 6 mM, also present in the bath). BL denotes the baseline response, and W, the response obtained after washing out DHPG. DHPG was
applied 3 times at 20-min intervals starting ,15–20 min after break-in. (b) Group data for experiments in (a);
*p,0.01, one way repeated ANOVA;
Scale: 20 ms/200 pA. (c) Sample eIPSCs (each trace is the mean of 3) response to 50 mM DHPG before and after repetitive DSI stimulation (1-s
depolarizing steps were given at 12-s intervals continuously for 4 min). (d) Group data showing that eCBmGluR was not affected by repetitive DSI
stimulation. Scale: 20 ms/200 pA.
doi:10.1371/journal.pone.0016305.g006
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Thus, our present data is consistent with, and extends, previous
proposals [26,27,28].
Factors that could be responsible for maintaining the hypothet-
ically distinct DAGLa (or DAG) pools are unknown. Physical
separation of protein components of the biosynthetic cascades,
perhaps sequestration on lipid rafts [29] or other factors related to
the heterogeneity of the lipid bilayer could be involved [28]. In this
context, it may also be worth noting that DAGLa
2/2 mice also
showed a reduction of ,50% in the levels of anandamide [7,8].
Therefore, although the greater reduction in 2-AG supports the
concept that 2-AG is the eCB that mediates many phasic CB1R-
dependent responses, the possibility cannot be eliminated that
anandamide might play a contributory role in some cases.
The model of 2-AG release from a pre-existing pool differs from
the conventional ‘‘on-demand’’ model of eCB production in which
synthesis and release are necessarily tightly coupled to each other.
The hypothesis may account in part for some of the multiple
mechanisms of eCB responses [20,26], and may help reconcile the
negative pharmacological reports with DAGL inhibitors, e.g. [25],
with data from the DAGL
2/2 studies [7,8]. The hypothesis would
also be consistent with evidence that 2-AG release is a regulated
step, perhaps involving the eCB transporter [30,31]. Testing this
idea and investigating the subcellular distribution and regulation of
DAGL in general will be important future tasks.
Methods
Preparation of slices
All experimental protocols were reviewed and approved by the
University of Maryland School of Medicine IACUC (IACUC
approval #0609001), and all animal handling was conducted in
accordance with national and international guidelines. The
number of animals used was minimized, and all necessary
precautions were taken to mitigate pain or suffering.
Hippocampal slices were obtained from 4- to 6-week-old male
Sprague-Dawley rats. After rats were sedated with isoflurane and
decapitated, the hippocampi were removed and 400-mm-thick slices
were cut on a Vibratome (model VT1200s, Leica Microsystems,
Inc., Bannockburn, IL) in an ice-cold extracellular recording
solution. Slices were stored in a holding chamber on filter paper
at the interface of this solution and a moist, oxygenated atmosphere
at room temperature for $1h before transfer to the recording
chamber (RC-27L, Warner Instruments, CT) and warmed to 30–
31uC. The extracellular solutioncontained (mM): 120 NaCl, 3 KCl,
2.5 CaCl2, 2 MgSO4, 1 NaH2PO4, 25 NaHCO3, and 20 glucose,
and was bubbled with 95%O2, 5%CO2 (pH 7.4).
Electrophysiology
Whole-cell voltage-clamp recordings of CA1 pyramidal cells
were made using the blind patch method. Pipettes were pulled
from thin walled glass capillaries (1.5 O.D., World Precision
Instruments, Sarasota, FL). Electrode resistances in the bath were
3–6 MV with internal solution containing (mM): 90 CsCH3SO4,1
MgCl2, 50 CsCl, 2 MgATP, 0.2 Cs4-BAPTA, 10 HEPES, 0.3 Tris
GTP and 5 QX314. If the series resistances, which was checked by
-2 mV voltage steps throughout experiments, changed .20%, the
data were discarded. The holding potential was -70 mV in all
experiments. Monosynaptic eIPSCs were elicited by 100-ms-long
extracellular stimuli delivered at 0.25 Hz with concentric bipolar
stimulating electrodes placed in s. radiatum. NBQX (10 mM) and
D-AP5 (20 mM) were present in all experiments to block
glutamatergic EPSCs. Slices were pretreated in the holding
chamber with the irreversible P/Q-type voltage-gated Ca
2+-
channel toxin, v-agatoxin GVIA (agatoxin, 300 nM) for $1h
to reduce the contribution of eCB-insensitive eIPSCs in all
experiments [32]. Data were collected with an Axopatch 1C
amplifier (Molecular Devices, Sunnyvale, CA), filtered at 1 kHz
and digitized at 5 kHz using a Digidata 1200 (Molecular Devices)
and Clampex 8 software (Molecular Devices).
The bath solution was oxygenated with 95% O2/5% CO2 gas,
and perfused continuously through the recording chamber at
,1 ml/min. For external applications, slices were preincubated
for .40 min with OMDM-188, THL, OMDM-169, DMSO, or
ethanol, and the drug was also present in the bath solution
throughout the recording. The final concentration of the solvent,
DMSO or ethanol, was 0.05% (v/v) or less for both OMDM-188
and THL. JZL184 was obtained from Cayman Chemical,
OMDM-188 and OMDM-169 was synthesized by Giorgio Ortar
and Enrico Morera, and all other chemicals were purchased from
Sigma (St. Louis, MO).
Data analysis
To measure DSI, we evoked IPSCs at 4-s intervals and
depolarized the postsynaptic cell to 0 mV for 1- 5 s at 90-s intervals.
The magnitude of DSI was calculated as follows: DSI (%) =1006
[1 - (mean of 4 IPSCs after depolarization/mean of 5 IPSCs before
depolarization)]. Values of 2 - 3 DSI trials were averaged for a given
condition. The decay time constant of DSI (tdecay) was determined
by fitting the data with a single-exponential decay function in
SigmaPlot 10.0. Two-tailed paired t-tests were used whenever
appropriate; otherwise unpaired t-tests were used for single
comparisons. Statistical tests among groups were done with one-
way ANOVA. For comparison of results from repeated DHPG
applications, we used one-way repeated ANOVA. The significance
level for all tests was p,0.05 (*). Group means 6 SEMs are shown
fordisplaypurposes.Forcomparisonofcumulativedistributions,we
used the Kolmogorov-Smirnov (K-S) test, available at http://www.
physics.csbsju.edu/stats/KS-test.n.plot_form.html.
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